Birdwatch Archive

Birdwatch Note

2024-09-30 06:44:12 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

レプリコンが治験で死者の話は重要な背景情報が欠けてます 本治験は A群:ワクチン→3か月程観察①A→プラセボ→4か月程観察②A B群:プラセボ→3か月間観察①B→ワクチン→4か月程観察②B の4期間で ①A死亡5(コロナ死1 ①B死亡16(コロナ死9 ②A死亡9 ②B死亡4 で全死亡は接種との因果関係が否定され(各群八千人程 下記pdf29p https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf#page=29 即ち有効性評価期間①でプラセボは3倍以上死亡です 24%の参加者が基礎疾患をもち(同45p https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf#page=45 17%が高齢者です https://www.nature.com/articles/s41467-024-47905-1/tables/1 11か月×八千人で18人死亡(①A②A②Bの和)はベトナムの年間死亡率の3分の1程です https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?locations=VN

Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1840641191563632648

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1840643793462390929
  • noteId - 1840643793462390929
  • participantId -
  • noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
  • createdAtMillis - 1727678652527
  • tweetId - 1840641191563632648
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 1
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 1
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • レプリコンが治験で死者の話は重要な背景情報が欠けてます 本治験は A群:ワクチン→3か月程観察①A→プラセボ→4か月程観察②A B群:プラセボ→3か月間観察①B→ワクチン→4か月程観察②B の4期間で ①A死亡5(コロナ死1 ①B死亡16(コロナ死9 ②A死亡9 ②B死亡4 で全死亡は接種との因果関係が否定され(各群八千人程 下記pdf29p https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf#page=29 即ち有効性評価期間①でプラセボは3倍以上死亡です 24%の参加者が基礎疾患をもち(同45p https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf#page=45 17%が高齢者です https://www.nature.com/articles/s41467-024-47905-1/tables/1 11か月×八千人で18人死亡(①A②A②Bの和)はベトナムの年間死亡率の3分の1程です https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?locations=VN

Note Ratings

rated at rated by
2024-09-30 19:26:06 -0500 Rating Details
2024-09-30 19:16:15 -0500 Rating Details
2024-09-30 18:46:45 -0500 Rating Details
2024-09-30 18:44:22 -0500 Rating Details
2024-09-30 18:37:54 -0500 Rating Details
2024-09-30 18:16:19 -0500 Rating Details
2024-09-30 18:15:34 -0500 Rating Details
2024-09-30 18:14:15 -0500 Rating Details
2024-09-30 17:40:19 -0500 Rating Details
2024-09-30 17:37:29 -0500 Rating Details
2024-09-30 17:19:32 -0500 Rating Details
2024-09-30 17:04:59 -0500 Rating Details
2024-09-30 16:37:27 -0500 Rating Details
2024-09-30 16:29:00 -0500 Rating Details
2024-09-30 15:31:45 -0500 Rating Details
2024-09-30 14:16:13 -0500 Rating Details
2024-09-30 13:54:00 -0500 Rating Details
2024-09-30 13:51:32 -0500 Rating Details
2024-09-30 13:34:15 -0500 Rating Details
2024-09-30 13:03:00 -0500 Rating Details
2024-09-30 12:39:48 -0500 Rating Details
2024-09-30 12:32:01 -0500 Rating Details
2024-09-30 12:01:49 -0500 Rating Details
2024-09-30 11:54:51 -0500 Rating Details
2024-09-30 11:26:58 -0500 Rating Details
2024-09-30 11:26:29 -0500 Rating Details
2024-09-30 11:23:02 -0500 Rating Details
2024-09-30 11:01:34 -0500 Rating Details
2024-09-30 10:17:34 -0500 Rating Details
2024-09-30 10:17:10 -0500 Rating Details
2024-09-30 10:16:45 -0500 Rating Details
2024-09-30 09:48:33 -0500 Rating Details
2024-09-30 09:36:28 -0500 Rating Details
2024-09-30 09:29:33 -0500 Rating Details
2024-09-30 08:46:33 -0500 Rating Details
2024-09-30 08:42:56 -0500 Rating Details
2024-09-30 08:38:15 -0500 Rating Details
2024-09-30 08:31:47 -0500 Rating Details
2024-09-30 08:31:25 -0500 Rating Details
2024-09-30 08:31:07 -0500 Rating Details
2024-09-30 08:11:48 -0500 Rating Details
2024-09-30 08:11:33 -0500 Rating Details
2024-09-30 08:04:11 -0500 Rating Details
2024-09-30 08:03:39 -0500 Rating Details
2024-09-30 07:47:58 -0500 Rating Details
2024-09-30 07:43:15 -0500 Rating Details
2024-09-30 07:42:53 -0500 Rating Details
2024-09-30 07:35:42 -0500 Rating Details
2024-09-30 07:34:12 -0500 Rating Details
2024-09-30 07:23:02 -0500 Rating Details
2024-09-30 07:02:29 -0500 Rating Details
2024-09-30 06:52:30 -0500 Rating Details
2024-09-30 06:50:13 -0500 Rating Details
2024-09-30 06:49:02 -0500 Rating Details
2024-09-30 06:46:07 -0500 Rating Details
2024-09-30 06:32:32 -0500 Rating Details
2024-09-30 06:21:11 -0500 Rating Details
2024-09-30 06:20:24 -0500 Rating Details
2024-09-30 06:14:05 -0500 Rating Details
2024-09-30 06:08:13 -0500 Rating Details
2024-09-30 06:06:45 -0500 Rating Details
2024-09-30 06:04:53 -0500 Rating Details
2024-09-30 06:02:11 -0500 Rating Details
2024-09-30 05:49:06 -0500 Rating Details
2024-09-30 05:48:29 -0500 Rating Details
2024-09-30 05:47:05 -0500 Rating Details
2024-09-30 05:41:41 -0500 Rating Details
2024-09-30 05:39:42 -0500 Rating Details
2024-09-30 05:37:35 -0500 Rating Details
2024-09-30 05:23:36 -0500 Rating Details
2024-09-30 05:20:43 -0500 Rating Details
2024-09-30 05:18:47 -0500 Rating Details
2024-09-30 05:11:51 -0500 Rating Details
2024-09-30 05:10:26 -0500 Rating Details
2024-09-30 05:08:30 -0500 Rating Details
2024-09-30 04:58:01 -0500 Rating Details
2024-09-30 04:51:33 -0500 Rating Details
2024-09-30 04:42:55 -0500 Rating Details
2024-09-30 04:38:26 -0500 Rating Details
2024-09-30 04:34:00 -0500 Rating Details
2024-09-30 04:33:24 -0500 Rating Details
2024-09-30 04:31:37 -0500 Rating Details
2024-09-30 04:29:32 -0500 Rating Details
2024-09-30 04:25:22 -0500 Rating Details
2024-09-30 04:18:03 -0500 Rating Details
2024-09-30 04:06:13 -0500 Rating Details
2024-09-30 03:58:28 -0500 Rating Details
2024-09-30 03:55:14 -0500 Rating Details
2024-09-30 03:54:28 -0500 Rating Details
2024-09-30 03:45:57 -0500 Rating Details
2024-09-30 03:36:12 -0500 Rating Details
2024-09-30 03:22:36 -0500 Rating Details
2024-09-30 03:20:10 -0500 Rating Details
2024-09-30 03:18:33 -0500 Rating Details
2024-09-30 03:16:31 -0500 Rating Details
2024-09-30 03:15:37 -0500 Rating Details
2024-09-30 03:10:54 -0500 Rating Details
2024-09-30 03:10:43 -0500 Rating Details
2024-09-30 03:08:46 -0500 Rating Details
2024-09-30 03:07:44 -0500 Rating Details
2024-09-30 03:00:22 -0500 Rating Details
2024-09-30 02:57:49 -0500 Rating Details
2024-09-30 02:54:54 -0500 Rating Details
2024-09-30 02:54:39 -0500 Rating Details
2024-09-30 02:51:42 -0500 Rating Details
2024-09-30 02:51:15 -0500 Rating Details
2024-09-30 02:46:13 -0500 Rating Details
2024-09-30 02:44:19 -0500 Rating Details
2024-09-30 02:39:58 -0500 Rating Details
2024-09-30 02:36:51 -0500 Rating Details
2024-09-30 02:36:34 -0500 Rating Details
2024-09-30 02:33:43 -0500 Rating Details
2024-09-30 02:30:34 -0500 Rating Details
2024-09-30 02:24:32 -0500 Rating Details
2024-09-30 02:23:28 -0500 Rating Details
2024-09-30 02:17:34 -0500 Rating Details
2024-09-30 02:16:22 -0500 Rating Details
2024-09-30 02:16:20 -0500 Rating Details
2024-09-30 02:13:20 -0500 Rating Details
2024-09-30 02:12:44 -0500 Rating Details
2024-09-30 02:12:02 -0500 Rating Details
2024-09-30 02:10:50 -0500 Rating Details
2024-09-30 02:10:00 -0500 Rating Details
2024-09-30 02:06:26 -0500 Rating Details
2024-09-30 02:02:37 -0500 Rating Details
2024-09-30 01:49:45 -0500 Rating Details
2024-10-02 03:46:22 -0500 Rating Details
2024-10-01 12:11:45 -0500 Rating Details
2024-10-01 11:09:10 -0500 Rating Details
2024-10-01 08:15:46 -0500 Rating Details
2024-10-01 08:07:53 -0500 Rating Details
2024-10-01 07:04:39 -0500 Rating Details
2024-10-01 06:20:30 -0500 Rating Details
2024-10-01 05:52:42 -0500 Rating Details
2024-10-01 00:07:21 -0500 Rating Details
2024-09-30 22:43:00 -0500 Rating Details
2024-09-30 22:39:08 -0500 Rating Details
2024-09-30 21:40:42 -0500 Rating Details
2024-09-30 21:39:37 -0500 Rating Details
2024-09-30 21:13:36 -0500 Rating Details
2024-09-30 20:36:25 -0500 Rating Details
2024-10-03 22:34:51 -0500 Rating Details
2024-10-03 12:29:06 -0500 Rating Details
2024-10-03 09:36:03 -0500 Rating Details
2024-10-03 07:22:06 -0500 Rating Details
2024-09-30 22:12:50 -0500 Rating Details
2024-09-30 20:35:00 -0500 Rating Details
2024-10-26 01:00:10 -0500 Rating Details
2024-10-12 00:09:51 -0500 Rating Details
2024-10-01 07:49:48 -0500 Rating Details
2024-10-01 06:25:25 -0500 Rating Details
2024-09-30 10:40:02 -0500 Rating Details
2024-09-30 10:11:40 -0500 Rating Details
2024-09-30 09:08:17 -0500 Rating Details
2024-09-30 09:02:12 -0500 Rating Details
2024-09-30 08:48:30 -0500 Rating Details
2024-09-30 08:14:16 -0500 Rating Details
2024-09-30 07:11:03 -0500 Rating Details
2024-09-30 06:10:45 -0500 Rating Details
2024-09-30 05:55:52 -0500 Rating Details
2024-09-30 05:19:49 -0500 Rating Details
2024-09-30 05:14:16 -0500 Rating Details
2024-09-30 05:09:23 -0500 Rating Details
2024-10-28 11:47:10 -0500 Rating Details
2024-10-06 12:03:31 -0500 Rating Details
2024-10-03 16:10:49 -0500 Rating Details
2024-10-03 05:20:51 -0500 Rating Details
2024-09-30 23:19:37 -0500 Rating Details